title: [Comparative evaluation of effectiveness of treatment of hyperprolactinemia].
abstract: The effectiveness of treatment of hyperprolactinemia (of functional and organic genesis) with dophamin agonists was studied in 97 women aged 18-32. The effectiveness was evaluated by normalization of the laboratory indices of prolactin level, and the clinical parameters: restoration of the regularity of the menstrual cycle; resumption of ovulation; becoming pregnant; stopping of galactorrhea. Dophamin agonists of the I generation, parlodel, and of the III generation, dostinex, were prescribed. The doses were selected individually, in accordance with the monthly indices of the prolactin level. The duration of treatment was 6 months with a subsequent 6-month follow-up. At micro- and macroadenomas of hypophysis, dostinex proved most effective and highly durable. Dostinex is characterized by infrequent occurrence of side effects; is particularly recommended in cases of parlodel resistance or intolerance. Parlodel may be a preparation of choice for treating all kinds of hyperprolactinemia conditions; no contraindication at becoming pregnant.
authors.forename: K A
authors.initials: KA
authors.lastname: Tokhunts
mesh_terms: D000236:Adenoma / Q000188:drug therapy* / Q000453:epidemiology; D000293:Adolescent; D000328:Adult; D001971:Bromocriptine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004873:Ergolines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy* / Q000453:epidemiology; D010060:Ovulation / Q000187:drug effects; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D016896:Treatment Outcome
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D001971:Bromocriptine; D000077465:Cabergoline